Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
5) Praluent (alirocumab) Praluent is indicated for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL cholesterol
But is it the only way to measure meaningful treatment success
Novo Nordisk (NVO) Trailing P/Es: LLY 38, NOV 10 Forward P/Es: LLY 26, NVO 11 Estimated 2026 sales growth: LLY 26%, NVO -8% Estimated 2025 EPS growth: LLY 43%, NVO -6% Cash per share: LLY $8.14, NVO $6.07 Institutional ownership: LLY 84.6%, NVO 9.5% In terms of value, NVO has LLY beat by a mile, trading at less than a third of LLY on a trailing price-to-earnings basis and just under half of it on a forward price-to-earnings basis
Accounts of people knocking off the pounds using the drug have contributed to a spiking demand and shortages
